- Home
- NUVL vs LYFT Comparison
NUVL vs LYFT Comparison
Compare NUVL & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LYFT
- Stock Information
- Founded
- NUVL 2017
- LYFT 2007
- Country
- NUVL United States
- LYFT United States
- Employees
- NUVL N/A
- LYFT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LYFT Business Services
- Sector
- NUVL Health Care
- LYFT Consumer Discretionary
- Exchange
- NUVL Nasdaq
- LYFT Nasdaq
- Market Cap
- NUVL 5.4B
- LYFT 6.3B
- IPO Year
- NUVL 2021
- LYFT 2019
- Fundamental
- Price
- NUVL $80.48
- LYFT $16.10
- Analyst Decision
- NUVL Strong Buy
- LYFT Buy
- Analyst Count
- NUVL 10
- LYFT 33
- Target Price
- NUVL $119.60
- LYFT $16.53
- AVG Volume (30 Days)
- NUVL 582.7K
- LYFT 14.2M
- Earning Date
- NUVL 08-07-2025
- LYFT 08-06-2025
- Dividend Yield
- NUVL N/A
- LYFT N/A
- EPS Growth
- NUVL N/A
- LYFT N/A
- EPS
- NUVL N/A
- LYFT 0.14
- Revenue
- NUVL N/A
- LYFT $5,958,987,000.00
- Revenue This Year
- NUVL N/A
- LYFT $14.15
- Revenue Next Year
- NUVL N/A
- LYFT $12.81
- P/E Ratio
- NUVL N/A
- LYFT $117.41
- Revenue Growth
- NUVL N/A
- LYFT 27.32
- 52 Week Low
- NUVL $55.54
- LYFT $8.93
- 52 Week High
- NUVL $113.51
- LYFT $19.07
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- LYFT 59.28
- Support Level
- NUVL $76.27
- LYFT $15.58
- Resistance Level
- NUVL $80.90
- LYFT $16.46
- Average True Range (ATR)
- NUVL 2.55
- LYFT 0.54
- MACD
- NUVL 0.19
- LYFT 0.05
- Stochastic Oscillator
- NUVL 81.61
- LYFT 86.47
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.